[The current status of adjuvant chemotherapy of colonic cancer].

PubWeight™: 0.75‹?›

🔗 View Article (PMID 19999632)

Published in Gan To Kagaku Ryoho on November 01, 2009

Authors

Hiroya Takiuchi

Articles by these authors

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol (2009) 5.19

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol (2010) 2.73

Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys (2010) 1.71

Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer (2002) 1.71

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol (2010) 1.69

Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol (2006) 1.34

Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol (2010) 1.16

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer (2011) 1.08

Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol (2007) 1.08

Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology (2005) 1.02

Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology (2008) 0.98

A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol (2009) 0.93

A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol (2006) 0.93

A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol (2008) 0.92

Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology (2008) 0.92

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer (2012) 0.92

Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens. Jpn J Clin Oncol (2007) 0.90

A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial). Gastric Cancer (2011) 0.89

A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol (2010) 0.88

Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. Jpn J Clin Oncol (2008) 0.88

Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res (2012) 0.86

Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets. Jpn J Clin Oncol (2004) 0.84

A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Invest New Drugs (2011) 0.81

Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). J Chemother (2013) 0.81

[Case of disseminated carcinomatosis of bone marrow with severe alkalinephosphatasia, manifested 10 years after resection of early gastric cancer]. Nihon Shokakibyo Gakkai Zasshi (2004) 0.80

Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial. Jpn J Clin Oncol (2007) 0.79

Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment. Gastric Cancer (2011) 0.79

A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer. Jpn J Clin Oncol (2012) 0.78

[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)]. Gan To Kagaku Ryoho (2010) 0.78

[Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer]. Gan To Kagaku Ryoho (2006) 0.77

Adjuvant therapy in rectal cancer: what is the truth? Jpn J Clin Oncol (2006) 0.77

Gastric mucosal cell protection by epidermal growth factor in primary monolayer culture of guinea pig gastric mucous cells. J Gastroenterol (2003) 0.77

A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC). Jpn J Clin Oncol (2007) 0.75

Application of electrolysis for detoxification of an antineoplastic in urine. Ecotoxicol Environ Saf (2011) 0.75

[A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine]. Gan To Kagaku Ryoho (2006) 0.75

Metastatic malignant melanoma. Gastrointest Endosc (2002) 0.75

[Serotonin syndrome in a patient with small cell lung cancer]. Gan To Kagaku Ryoho (2013) 0.75

[A resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer]. Gan To Kagaku Ryoho (2010) 0.75

[Chemotherapy for gastrointestinal cancer in elderly patients]. Gan To Kagaku Ryoho (2011) 0.75

[A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU]. Gan To Kagaku Ryoho (2004) 0.75

[Lower G. I./colon and rectum cancer. IV. Standard chemotherapy of advanced, recurrent colonic cancer]. Gan To Kagaku Ryoho (2010) 0.75

[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)]. Gan To Kagaku Ryoho (2011) 0.75

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS. Jpn J Clin Oncol (2010) 0.75

[Comparison of chemotherapy side effects between elderly and young subjects]. Gan To Kagaku Ryoho (2012) 0.75

Evaluation of an electrolysis apparatus for inactivating antineoplastics in clinical wastewater. Chemosphere (2008) 0.75

[Current status and perspectives of biologics in the treatment of metastatic colorectal cancer]. Nihon Rinsho (2010) 0.75

[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer]. Gan To Kagaku Ryoho (2002) 0.75

[S-1 combined with weekly paclitaxel in patients with advanced gastric cancer]. Gan To Kagaku Ryoho (2006) 0.75

Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102. Jpn J Clin Oncol (2007) 0.75

A problem-based learning tutorial for dental students regarding elderly residents in a nursing home in Japan. J Dent Educ (2012) 0.75